Top PD-1 and PD-L1 Inhibitors companies

The 6 key players our PD-1 and PD-L1 Inhibitors report profiles, and other companies free public records show in this market.

Key players in PD-1 and PD-L1 Inhibitors

In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.

Also active in PD-1 and PD-L1 Inhibitors

Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.

Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.

Top trial sponsors in PD-1 and PD-L1 Inhibitors

Companies leading the most active studies found with this market's trial search, worldwide (key players included).

  1. Merck & Co., Inc. 54 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Sichuan Baili Pharmaceutical Co., Ltd. 20 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Akeso 12 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Regeneron Pharmaceuticals 10 active trials on ClinicalTrials.gov (opens in a new tab)
  5. AstraZeneca 9 active trials on ClinicalTrials.gov (opens in a new tab)
  6. Shanghai Henlius Biotech 7 active trials on ClinicalTrials.gov (opens in a new tab)
  7. BioNTech 6 active trials on ClinicalTrials.gov (opens in a new tab)
  8. Gilead Sciences, Inc. 6 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

PD-1 and PD-L1 Inhibitors reports by place

One report for each place. Each tile opens that place's report.

Regions 7

Countries 26

Compare all 33 places for PD-1 and PD-L1 Inhibitors, with active trials

Get the full PD-1 and PD-L1 Inhibitors report

Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.

Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.